User:Mr. Ibrahem/Lurbinectedin

Lurbinectedin, sold under the brand name Zepzelca, is a medication used to treat small cell lung cancer (SCLC). It is used when the disease has spread despite other treatments. It is given by gradual injection into a vein.

Common side effects include low white blood cells, low red blood cells, kidney problems, low platelets, nausea, muscle pain, shortness of breath, liver inflammation, and constipation. Other side effects may include infertility. Use in pregnancy may harm the baby. It is an alkylating agent. It works by interfering with DNA duplication required for cell division.

Lurbinectedin was approved for medical use in the United States in 2020 and Australia in 2021. In the United States 4 mg costs about 7,200 USD as of 2021. As of 2021 it is not available in the United Kingdom or Europe.